Form 4/A for AKTX Akari Therapeutics Plc
Accepted 2025-02-07 00:00:00 ET · period of report 2025-01-10 · accession 0000950170-25-016334 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2025-02-07 | 2025-01-10 | AKTX | Gaslightwala Abizer | Dir | A - Grant | $1.22 | +11.6K | 47.5K | +32% | +$14.2K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depository Shares representing Ordinary Shares | 2025-01-10 | A | A | 11,640 | $1.22 | 47,500 | D | — | — | (F1) Each American Depository Share ("ADS") represents 2,000 Ordinary Shares with a par value of $0.0001 per Ordinary Share of the Issuer. (F2) On January 13, 2025, the Reporting Person previously reported the purchase of 11,439 ADS at purchase price of $1.22 per ADS. The Reporting Person actually acquired 11,640 ADS at a price raning from $1.22 per ADS to $1.28 per ADS. The Reporting Person also previously reported the total amount of securities beneficially owned following transaction as 35,860 and omitted the ADS acquired on January 10, 2025. The revised amount of securities beneficially owned following the transaction is 47,500 ADS. |